# Simponi® (simponi) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/simponi

> Simponi® (simponi), sponsored by Alvotech (ALVO): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Simponi® (simponi) |
| Codes |  |
| Sponsor | Alvotech (ALVO) https://sec-api.dev/companies/alvo/catalysts |
| Indications | [moderate to severe rheumatoid arthritis](https://sec-api.dev/indications/moderate-to-severe-rheumatoid-arthritis) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Nov 2023: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-01-27, last confirmed 2025-11-20.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-007451): "In November 2023, Alvotech announced positive topline results from a pharmacokinetic study which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® in healthy adult participants (clintrials.gov/study/NCT05632211)." https://www.sec.gov/Archives/edgar/data/1898416/000117184325007451/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-006012): "In November 2023, Alvotech announced positive topline results from a pharmacokinetic study which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® in healthy adult participants." https://www.sec.gov/Archives/edgar/data/1898416/000117184325006012/exh_993.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000421): "Previously, in November 2023, Alvotech announced positive topline results from a pharmacokinetic study which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® in healthy adult participants." https://www.sec.gov/Archives/edgar/data/1898416/000117184325000421/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-003438): "In November 2023 , the Company announced positive topline results from the pharmacokinetic study for AVT 05 ." https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_992.htm
- SEC Form 10-K (accession 0001628280-25-015052): "In November 2023, we announced positive topline results from our pharmacokinetic study for AVT05." https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm

### Apr 2024: topline data readout

- Status: completed, positive. Date confidence: month. Indication: moderate to severe rheumatoid arthritis.
- First seen 2025-01-27, last confirmed 2025-11-20.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-007451): "In April 2024, Alvotech announced positive top-line results from a confirmatory clinical study comparing efficacy, safety, and immunogenicity between its biosimilar candidate AVT05 and the reference product Simponi® in patients with moderate to severe rheumatoid arthritis (clintrials.gov/study/NCT05842213)." https://www.sec.gov/Archives/edgar/data/1898416/000117184325007451/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000421): "In April 2024, Alvotech announced positive top-line results from a confirmatory clinical study comparing efficacy, safety, and immunogenicity between AVT05 and Simponi® in patients with moderate to severe rheumatoid arthritis." https://www.sec.gov/Archives/edgar/data/1898416/000117184325000421/exh_991.htm

## Same indication

- [Aria® (golimumab)](https://sec-api.dev/pdufa/golimumab) (JNJ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/simponi.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Simponi® (simponi) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/simponi

```bibtex
@misc{secapidev_pdufa_simponi_20261116,
  title        = {Simponi® (simponi) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/simponi}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_simponi_20261116","title":"Simponi® (simponi) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/simponi","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
